Technical Analysis for YMAB - Y-mAbs Therapeutics, Inc.

Grade Last Price % Change Price Change
C 10.02 1.42% 0.14
YMAB closed up 1.42 percent on Friday, May 20, 2022, on 78 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up

Date Alert Name Type % Chg
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Crossed Above 20 DMA Bullish 1.42%
Multiple of Ten Bearish Other 1.42%
Wide Bands Range Expansion 1.42%
Fell Below 20 DMA Bearish 5.25%
Calm After Storm Range Contraction 5.25%
Multiple of Ten Bearish Other 5.25%
Wide Bands Range Expansion 5.25%
Gapped Down Weakness 5.25%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1% about 15 hours ago
60 Minute Opening Range Breakdown about 18 hours ago
Up 5% about 19 hours ago
Rose Above Previous Day's High about 19 hours ago
Up 3% about 19 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Cancer Treatment Therapeutic Products Blastoma Cancer Center Brain Tumor Metastases Glioma Neuroblastoma Diffuse Intrinsic Pontine Glioma Kettering Cancer Center Memorial Sloan Refractory

Is YMAB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 39.74
52 Week Low 6.5
Average Volume 484,109
200-Day Moving Average 17.85
50-Day Moving Average 11.00
20-Day Moving Average 9.44
10-Day Moving Average 9.53
Average True Range 1.04
RSI 49.75
ADX 18.43
+DI 24.11
-DI 22.77
Chandelier Exit (Long, 3 ATRs) 9.77
Chandelier Exit (Short, 3 ATRs) 10.45
Upper Bollinger Bands 10.92
Lower Bollinger Band 7.95
Percent B (%b) 0.7
BandWidth 31.45
MACD Line -0.32
MACD Signal Line -0.48
MACD Histogram 0.1565
Fundamentals Value
Market Cap 405.95 Million
Num Shares 40.5 Million
EPS -1.83
Price-to-Earnings (P/E) Ratio -5.48
Price-to-Sales 0.00
Price-to-Book 16.71
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.12
Resistance 3 (R3) 11.15 10.81 10.93
Resistance 2 (R2) 10.81 10.53 10.80 10.87
Resistance 1 (R1) 10.42 10.36 10.25 10.39 10.81
Pivot Point 10.08 10.08 10.00 10.07 10.08
Support 1 (S1) 9.69 9.80 9.52 9.66 9.23
Support 2 (S2) 9.35 9.63 9.34 9.17
Support 3 (S3) 8.96 9.35 9.11
Support 4 (S4) 8.93